GMP FirstEnergy Sticks to Their Buy Rating for Spectral Medical

By Austin Angelo

Wall Street analyst has provided a review for the Healthcare company yesterday, but retained the same rating on the stock. Analyst Martin Landry from GMP FirstEnergy reiterated a Buy rating on Spectral Medical (TSX: EDT), with a C$1 price target.

Landry has an average return of 35.4% when recommending Spectral Medical.

According to, Landry is ranked #633 out of 4569 analysts.

Spectral Medical has an analyst consensus of Moderate Buy, with a price target consensus of C$1.

Spectral Medical’s market cap is currently C$111.9M and has a P/E ratio of 0.

Spectral Medical, Inc. engages in the development and commercialization of the theranostic treatment for severe sepsis and septic shock. The company’s products include Endotoxin Activity Assay and Toraymyxin. The Endotoxin Activity Assay identifies patients at risk of developing sepsis and certain proprietary biological reagents. The Toraymyxin acts as Polymyxin B extracorporeal direct hemoperfusion device that removes circulating endotoxin from the bloodstream. The company was founded on July 29, 1991 and is headquartered in Toronto, Canada.

The company’s shares closed last Tuesday at $0.54.